Management

Biography

Mainga Hamaluba MBChB MD FRCPCH Head of Clinical Research. Mainga is a paediatrician and works on clinical trials of vaccines, human infections studies and neonatal care. She is Principal Investigator (PI) and lead of the R21 clinical development programme in Kenya which includes the first evaluation of R21 in Africa (Phase 1b and the ongoing phase 3 trials). This is complemented by a vaccine efficacy Human Infection Study where she is Co-PI. Furthermore, she is PI for a phase 1/2 (First-In-Human and phase 2 trial of the leading tetravalent candidate shigella vaccine); sponsored by LimmaTech Biologics Ag. She also has clinical oversight of the broad portfolio of KWTRP team Human Infection Study platforms for malaria and shigella. These complementary programs continue to accelerate the clinical development of malaria and shigella vaccines.

Current Work

Her current research focus is part of the Calestous Juma Fellowship funded by the Bill and Melinda Gates Foundation. This fellowship supports setting up a platform trial of neonatal interventions in coastal Kenya with a plan to expand this regionally to reduce neonatal mortality. She is currently supervising 1 PhD student working on snakebite research and has co-supervised MSc and PGDip studentships. She is currently PI or Co-PI of 9 clinical trials.

Collaborations

No active details yet

Project Research

No active details yet



Publications

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo, M. S., Dicko, A., Tinto, H., Ouédraogo, J. B., Hamaluba, M., Olotu, A., Beaumont, E., Ramos Lopez, F., Natama, H. M., Weston, S., Chemba, M., Compaore, Y. D., Issiaka, D., Salou, D., Some, A. M., Omenda, S., Lawrie, A., Bejon, P., Rao, H., Chandramohan, D., Roberts, R., Bharati, S., Stockdale, L., Gairola, S., Greenwood, B. M., Ewer, K. J., Bradley, J., Kulkarni, P. S., Shaligram, U., Hill, A. V. S.
Lancet, (2024). 403:533-544

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo, M. S., Dicko, A., Tinto, H., Ouédraogo, J. B., Hamaluba, M., Olotu, A., Beaumont, E., Ramos Lopez, F., Natama, H. M., Weston, S., Chemba, M., Compaore, Y. D., Issiaka, D., Salou, D., Some, A. M., Omenda, S., Lawrie, A., Bejon, P., Rao, H., Chandramohan, D., Roberts, R., Bharati, S., Stockdale, L., Gairola, S., Greenwood, B. M., Ewer, K. J., Bradley, J., Kulkarni, P. S., Shaligram, U., Hill, A. V. S.
Lancet, (2024). 403:533-544

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo, M. S., Dicko, A., Tinto, H., Ouédraogo, J. B., Hamaluba, M., Olotu, A., Beaumont, E., Ramos Lopez, F., Natama, H. M., Weston, S., Chemba, M., Compaore, Y. D., Issiaka, D., Salou, D., Some, A. M., Omenda, S., Lawrie, A., Bejon, P., Rao, H., Chandramohan, D., Roberts, R., Bharati, S., Stockdale, L., Gairola, S., Greenwood, B. M., Ewer, K. J., Bradley, J., Kulkarni, P. S., Shaligram, U., Hill, A. V. S.
Lancet, (2024). 403:533-544

Where do those data go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya.
Downs, L. O., Campbell, C., Abouyannis, M., Otiende, M., Kapulu, M., Obiero, C. W., Hamaluba, M., Ngetsa, C., Andersson, M. I., Githinji, G., Warimwe, G., Baisley, K., Scott, J. A. G., Matthews, P. C., Etyang, A.
J Virus Erad, (2023). 9:100355

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.
Odera, D. O., Tuju, J., Mwai, K., Nkumama, I. N., Fürle, K., Chege, T., Kimathi, R., Diehl, S., Musasia, F. K., Rosenkranz, M., Njuguna, P., Hamaluba, M., Kapulu, M. C., Frank, R., Osier, F. H. A., Abdi, A. I., Chi, P. C., de Laurent, Z., Jao, I., Kamuya, D., Kamuyu, G., Makale, J., Murungi, L., Musyoki, J., Muthui, M., Mwacharo, J., Kariuki, S., Mwanga, D., Mwongeli, J., Ndungu, F., Njue, M., Nyangweso, G., Kimani, D., Ngoi, J. M., Musembi, J., Ngoto, O., Otieno, E., Ooko, M., Shangala, J., Wambua, J., Mohammed, K. S., Omuoyo, D., Mosobo, M., Kibinge, N., Kinyanjui, S., Bejon, P., Lowe, B., Marsh, K., Marsh, V., Abebe, Y., Billingsley, P. F., Sim, B. K. L., Hoffman, S. L., James, E. R., Richie, T. L., Audi, A., Olewe, F., Oloo, J., Ongecha, J., Ongas, M. O., Koskei, N., Bull, P. C., Hodgson, S. H., Kivisi, C., Imwong, M., Murphy, S. C., Ogutu, B., Tarning, J., Winterberg, M., Williams, T. N.
Sci Transl Med, (2023). 15:eabn5993

[A global core outcome measurement set for snakebite clinical trials].
Abouyannis, M., Esmail, H., Hamaluba, M., Ngama, M., Mwangudzah, H., Mumba, N., Yeri, B. K., Mwalukore, S., Alphan, H. J., Aggarwal, D., Alcoba, G., Cammack, N., Chippaux, J. P., Coldiron, M. E., Gutiérrez, J. M., Habib, A. G., Harrison, R. A., Isbister, G. K., Lavonas, E. J., Martins, D., Ribeiro, I., Watson, J. A., Williams, D. J., Casewell, N. R., Walker, S. A., Lalloo, D. G.
Med Trop Sante Int, (2023). 3:mtsi.v3i3.2023.421

A long-term observational study of paediatric snakebite in Kilifi County, south-east Kenya.
Abouyannis, M., Boga, M., Amadi, D., Ouma, N., Nyaguara, A., Mturi, N., Berkley, J. A., Adetifa, I. M., Casewell, N. R., Lalloo, D. G., Hamaluba, M.
PLoS Negl Trop Dis, (2023). 17:e0010987

Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial.
Wamae, K., Ndwiga, L., Kharabora, O., Kimenyi, K., Osoti, V., de Laurent, Z., Wambua, J., Musyoki, J., Ngetsa, C., Kalume, P., Mwambingu, G., Hamaluba, M., van der Pluijm, R., Dondorp, A. M., Bailey, J., Juliano, J., Bejon, P., Ochola-Oyier, L.
Wellcome Open Res, (2022). 7:95

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Kimathi, D., Juan-Giner, A., Orindi, B., Grantz, K. H., Bob, N. S., Cheruiyot, S., Hamaluba, M., Kamau, N., Fall, G., Dia, M., Mosobo, M., Moki, F., Kiogora, K., Chirro, O., Thiong'o, A., Mwendwa, J., Guantai, A., Karanja, H. K., Gitonga, J., Mugo, D., Ramko, K., Faye, O., Sanders, E. J., Grais, R. F., Bejon, P., Warimwe, G. M.
Lancet Infect Dis, (2023). S1473-3099:00114-7

A global core outcome measurement set for snakebite clinical trials.
Abouyannis, M., Esmail, H., Hamaluba, M., Ngama, M., Mwangudzah, H., Mumba, N., Yeri, B. K., Mwalukore, S., Alphan, H. J., Aggarwal, D., Alcoba, G., Cammack, N., Chippaux, J. P., Coldiron, M. E., Gutierrez, J. M., Habib, A. G., Harrison, R. A., Isbister, G. K., Lavonas, E. J., Martins, D., Ribeiro, I., Watson, J. A., Williams, D. J., Casewell, N. R., Walker, S. A., Lalloo, D. G., Snakebite Global Core Outcome Set Study, Group
Lancet Glob Health, (2023). 11:e296-e300